Treatment and Outcomes among Patients with Cryptococcus gattii Infections in the United States Pacific Northwest

Background Cryptococcus gattii is a fungal pathogen causing an emerging outbreak in the United States Pacific Northwest (PNW). Treatment guidelines for cryptococcosis are primarily based on data from C. neoformans infections; applicability to PNW C. gattii infection is unknown. We evaluated the relationship between initial antifungal treatment and outcomes for PNW C.gattii patients. Methods Cases were defined as culture-confirmed invasive C. gattii infections among residents of Oregon and Washington States during 2004–2011. Clinical data were abstracted from medical records through one year of follow-up. Recommended initial treatment for central nervous system (CNS), bloodstream, and severe pulmonary infections is amphotericin B and 5-flucytosine; for non-severe pulmonary infections, recommended initial treatment is fluconazole. Alternative initial treatment was defined as any other initial antifungal treatment. Results Seventy patients survived to diagnosis; 50 (71%) received the recommended initial treatment and 20 (29%) received an alternative. Fewer patients with pulmonary infections [21 (64%)] than CNS infections [25 (83%)] received the recommended initial treatment (p = 0.07). Among patients with pulmonary infections, those with severe infections received the recommended initial treatment less often than those with non-severe infections (11% vs. 83%, p<0.0001). Eight patients with severe pulmonary infections received alternative initial treatments; three died. Four patients with non-severe pulmonary infections received alternative initial treatments; two died. There was a trend towards increased three-month mortality among patients receiving alternative vs. recommended initial treatment (30% vs. 14%, p = 0.12), driven primarily by increased mortality among patients with pulmonary disease receiving alternative vs. recommended initial treatment (42% vs. 10%, p = 0.07). Conclusions C.gattii patients with pulmonary infections – especially severe infections – may be less likely to receive recommended treatment than those with CNS infections; alternative treatment may be associated with increased mortality. Reasons for receipt of alternative treatment among C.gattii patients in this area should be investigated, and clinician awareness of recommended treatment reinforced.

[1]  D. Vugia,et al.  Cryptococcus gattii Infections in Multiple States Outside the US Pacific Northwest , 2013, Emerging infectious diseases.

[2]  K. Byth,et al.  Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Jinyoung Yoo,et al.  Pulmonary Cryptococcosis Mimicking Primary Lung Cancer with Multiple Lung Metastases , 2012, Tuberculosis and respiratory diseases.

[4]  T. Nagayasu,et al.  [Post-renal transplant pulmonary cryptococcosis, which was difficult to differentiate from a pulmonary tumor]. , 2012, Kyobu geka. The Japanese journal of thoracic surgery.

[5]  H. Fujimoto,et al.  [Pulmonary cryptococcosis preoperatively diagnosed as lung cancer]. , 2012, Kyobu geka. The Japanese journal of thoracic surgery.

[6]  S. Lockhart,et al.  Cryptococcus gattii: where do we go from here? , 2012, Medical mycology.

[7]  S. Maloney,et al.  High Prevalence of Cryptococcal Infection Among HIV-Infected Patients Hospitalized With Pneumonia in Thailand , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Harris,et al.  Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  S. Lockhart,et al.  Fatal Disseminated Cryptococcus gattii Infection in New Mexico , 2011, PloS one.

[10]  J. Heitman,et al.  Cryptococcus gattii genotype VGI infection in New England. , 2011, The Pediatric infectious disease journal.

[11]  D. Boulware.  Cryptococcus: from human pathogen to model yeast , 2011 .

[12]  B. Gazzard,et al.  HIV‐associated central nervous system diseases in the recent combination antiretroviral therapy era , 2011, European journal of neurology.

[13]  A. Casadevall,et al.  The History of Cryptococcus and Cryptococcosis , 2011 .

[14]  R. Wilkinson,et al.  Central nervous system disorders after starting antiretroviral therapy in South Africa , 2010, AIDS.

[15]  D. Castelo-Branco,et al.  Molecular methods for the diagnosis and characterization of Cryptococcus: a review. , 2010, Canadian journal of microbiology.

[16]  J. Perfect,et al.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Morshed,et al.  Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999–2007 , 2010, Emerging infectious diseases.

[18]  J. Heitman,et al.  Cryptococcus: from human pathogen to model yeast. , 2010 .

[19]  J. Heitman,et al.  First Reported Case of Cryptococcus gattii in the Southeastern USA: Implications for Travel-Associated Acquisition of an Emerging Pathogen , 2009, PloS one.

[20]  T. G. Mitchell,et al.  Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. , 2009, The Journal of infectious diseases.

[21]  R. Kaur,et al.  Profile of Central Nervous System Disease in HIV/AIDS Patients With Special Reference to Cryptococcal Infections , 2008, The neurologist.

[22]  S. Mithani,et al.  Cryptococcus gattii infections on Vancouver Island, British Columbia, Canada: emergence of a tropical fungus in a temperate environment. , 2008, Canada communicable disease report = Releve des maladies transmissibles au Canada.

[23]  T. Boekhout,et al.  Six monophyletic lineages identified within Cryptococcus neoformans and Cryptococcus gattii by multi-locus sequence typing. , 2008, Fungal genetics and biology : FG & B.

[24]  T. Boekhout,et al.  Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. , 2008, Revista iberoamericana de micologia.

[25]  P. Cieslak,et al.  Spread of Cryptococcus gattii in British Columbia, Canada, and Detection in the Pacific Northwest, USA , 2007, Emerging infectious diseases.

[26]  J. Heitman,et al.  Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak , 2005, Nature.

[27]  Jianping Xu,et al.  Comparative Gene Genealogies Indicate that Two Clonal Lineages of Cryptococcus gattii in British Columbia Resemble Strains from Other Geographical Areas , 2005, Eukaryotic Cell.

[28]  Y. Hirakata,et al.  Community acquired pneumonia (CAP) caused by Cryptococcus neoformans in a healthy individual , 2005, Scandinavian journal of infectious diseases.

[29]  T. Boekhout,et al.  A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Netea,et al.  Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon- gamma therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  P. Mwinzi,et al.  Intrathecal production and secretion of vascular endothelial growth factor during Cryptococcal Meningitis. , 2004, The Journal of infectious diseases.

[32]  N. White,et al.  Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial , 2004, The Lancet.

[33]  L. Castañón-Olivares,et al.  Cryptococcus neoformàns var. gattii among patients with cryptococcal meningitis in Mexico. First observations , 2004, Mycopathologia.

[34]  W. Meyer,et al.  Molecular Typing of IberoAmerican Cryptococcus neoformans Isolates , 2003, Emerging infectious diseases.

[35]  K. Byth,et al.  Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  J. Perfect,et al.  Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  R. Arreguín-Espinosa,et al.  Frequency of Cryptococcus species and varieties in México and their comparison with some Latin American countries. , 2000, Revista latinoamericana de microbiologia.

[38]  S Ie,et al.  Cryptococcus neoformans. , 1998, The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society.

[39]  P. Reiss,et al.  Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS‐associated cryptococcal meningitis , 1997, AIDS.

[40]  M. Saag,et al.  Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. , 1997, The New England journal of medicine.

[41]  D. Warrell,et al.  Visual loss in immunocompetent patients with Cryptococcus neoformans var. gattii meningitis. , 1997, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[42]  D. Warrell,et al.  Predictors of outcome in Cryptococcus neoformans var. gattii meningitis. , 1996, QJM : monthly journal of the Association of Physicians.

[43]  D. Dunt,et al.  Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  D. Lalloo,et al.  Cryptococcal meningitis (C. neoformans var. gattii) leading to blindness in previously healthy Melanesian adults in Papua New Guinea. , 1994, The Quarterly journal of medicine.

[45]  M. Saag,et al.  A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. , 1992, The New England journal of medicine.

[46]  M. Saag,et al.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. , 1992, The New England journal of medicine.

[47]  L. Chan,et al.  Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. , 1990, Annals of internal medicine.

[48]  D. Ellis.  Cryptococcus neoformans var. gattii in Australia , 1987, Journal of clinical microbiology.

[49]  K. Kwon-Chung,et al.  High prevalence of Cryptococcus neoformans var. gattii in tropical and subtropical regions. , 1984, Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology.

[50]  K. Kwon-Chung,et al.  Epidemiologic differences between the two varieties of Cryptococcus neoformans. , 1984, American journal of epidemiology.

[51]  D. Alling,et al.  A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. , 1979, The New England journal of medicine.

[52]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.

[53]  D. Alling,et al.  DIAGNOSTIC AND PROGNOSTIC VALUE OF CLINICAL AND LABORATORY FINDINGS IN CRYPTOCOCCAL MENINGITIS, A FOLLOW-UP STUDY OF FORTY PATIENTS. , 1964, The New England journal of medicine.